Fraunhofer MEVIS coordinates EU-project for further development of an innovative, conservative therapy
Tumor removal without a scalpel or x-rays is now possible due to a special type of ultrasound. Strong, concentrated ultrasonic waves are directed at the patient’s body in such a way that they heat and kill individual cancer cells.
Illustration of numerically simulated high-intensity focused ultrasound therapy.
A new EU-project wants to transfer this emerging, non-invasive therapy to moving organs, specifically the liver. The Fraunhofer MEVIS Institute for Medical Image Computing Bremen is coordinating “TRANS-FUSIMO”.
At present, the “focused ultrasound (FUS) therapy” is approved for only two diseases – prostate cancer and selected uterine myoma. These can be treated without surgery or exposure to radiation, though liver tumors cannot due to the motion of the organ caused by respiratory movement.
This movement complicates pointing the concentrated ultrasonic wave on the tumor, as the emitted heat spreads over a larger area, inhibiting its desired effect. There is also a higher risk of damaging the surrounding tissue, not achieving the desired therapy outcome. In this case, recurrences of the tumor may occur.
Over the past three years, the scope of the EU funded project, FUSIMO (“Patient Specific Modelling and Simulation of Focused Ultrasound In Moving Organs”, www.fusimo.eu), has laid the foundation for transferring FUS to moving organs.
The first step is to obtain 3D images from magnetic resonance tomography (MRT) that show the inside of the patient’s abdomen and simultaneously register the respiratory movements. Based on this data, experts can perform computer simulations of ultrasound treatment on the liver.
In the simulation, our software computes how the liver moves under respiration and thus can direct the virtual ultrasonic waves in such a way that they follow the movement of the liver and remain focused on the tumor. “In the future, such simulations can enable physicians to plan complex ultrasound interventions individual to the patient and in great detail”, says MEVIS-researcher Jan Strehlow.
“This is especially important in moving organs and can be decisive for indication whether this method of therapy is a viable option for a patient.” Furthermore, computer simulations may help shorten the duration of the ultrasound treatment.
The EU-Project, TRANS-FUSIMO, enables experts to take the next step: they strive to transfer virtual principles into real world applications and develop a system for patient treatment in the clinic. For this, a MR-scanner with a strong ultrasonic transmitter and a regular ultrasonic device are to be combined.
The latter registers the movement of the liver during respiration, in real time, while the patient is in the MR-scanner. Based on this data, the software calculates the path that the strong ultrasonic wave should take in order to stay focused on the tumor in spite of respiratory movement. During the treatment, the MR-scanner measures the distribution of temperature in the abdominal region, which allows physicians to precisely control the ultrasonic rays to target the tumor as desired.
Fraunhofer MEVIS is coordinating this EU-project and developing real-time control of all hardware systems. “Our aim is a product-capable system, for which we seek clinical approval”, says MEVIS-researcher Sabrina Haase. Over the next two years, the technology is to be tested on patients under general anesthesia; their breathing will be artificially halted, so that there is no liver movement for a short period of time. In 2018, the first patients without anesthesia are to be treated while breathing naturally. If these studies yield positive results, the new procedure may be approved.
The Fraunhofer Institute for Medical Image Computing MEVIS
Embedded in a worldwide network of clinical and academic partners, Fraunhofer MEVIS develops real-world software solutions for image-supported early detection, diagnosis, and therapy. Strong focus is placed on cancer as well as diseases of the circulatory system, brain, breast, liver, and lung. The goal is to detect diseases earlier and more reliably, tailor treatments to each individual, and make therapeutic success more measurable. In addition, the institute develops software systems for industrial partners to undertake image-based studies to determine the effectiveness of medicine and contrast agents. To reach its goals, Fraunhofer MEVIS works closely with medical technology and pharmaceutical companies, providing solutions for the entire chain of development from applied research to certified medical products. http://www.mevis.fraunhofer.de/en
TRANS-FUSIMO stands for “Clinical Translation of Patient-Specific Planning and Conducting of FUS Treatment in Moving Organs”. The EU-project was launched in January 2014 and will run for a period of five years with approximately 5.6 mil Euros in funding. Ten institutes from seven countries, including clinics, universities and four medical engineering institutes are participating. The Fraunhofer MEVIS Institute for Medical Image Computing Bremen is coordinating TRANS-FUSIMO.
Bianka Hofmann | Fraunhofer MEVIS
UTSA study describes new minimally invasive device to treat cancer and other illnesses
02.12.2016 | University of Texas at San Antonio
Earlier Alzheimer's diagnosis may be possible with new imaging compound
02.11.2016 | Washington University School of Medicine
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy